Lipoxen Share Discussion Threads

[pegasus59] 27/10/2010 08:29

serum institute of india mentioned as a possible beneficiary

peg

[buywell2] 25/10/2010 10:35

Very informative

Note that it was Baxter that asked for the warrants PLUS a director on the board AND the addition of 2 extra blood factor candidates to the original agreement.

Stock options of 20p, 40p and 100p show management still believe in their company

My take is that there has been a major seller off-loading from 15p and selling at 9p , could be that when they have sold out the share price will rebound.

If this coincides with news from India , which Maguire says is looking good .... then 15p could be hit sooner than many expect.

[rkhl] 24/10/2010 13:12

Nice find, LPX has got huge potential but I am afraid the market is becoming more and more dominated by investors looking for short term gains which is why the share price is where it is. I also think institutions are wary about supporting small pharma's as they have a mixed track record.

Really good interview and he's right, its all been positive news and I have little doubt that EPO P2 will be good news as well. He won't be drawn on EPO P2 results date though which makes me think it's going to come in very late according to the previous schedule.

I think LPX has got a great future, my only concern being how they fund themselves over the next 4 years. Maybe Baxter will takeover the company.

[aim_trader] 24/10/2010 10:41

"Scott Maguire, CEO of Lipoxen, says it's a mystery why his company's share price is so low

Sunday, October 24, 2010

Scott Maguire, CEO of Lipoxen, tells Proactive Investors why it's a mystery that his company's share price remains so low. He points to strengthened ties with US giant Baxter International plus positive results in trials for the company's influenza and flu treatments as reasons for a bright future."

[buywell2] 22/10/2010 09:01

''He said that the company will now seek EU grant funding to take their proprietary product into the clinic as soon as possible.''

I guess Maguire would not have said this unless he thought he had a decent chance of getting it.

Lipoxen reports positive results for its flu vaccine
by Tina Redlup on October 20, 2010
ShareThis


Scott Maguire
Officials with Lipoxen announced this week that preliminary tests show that its new influenza vaccine appears to be effective.

The new vaccine uses a liposomal co-delivery technology named ImuXen, ProactiveInvestors reports.

In April of 2009, Lipoxen officials announced positive clinical data that showed that ImuXen technology platform applied to an influenza vaccine increased the effectiveness of influenza vaccines by around 30-fold.

At that time, officials also said that ImuXen has the potential to increase output of vaccine doses from manufacturing facilities and that the vaccine was stable for long periods in high temperatures in its dried form, ProactiveInvestors.com reports.

Lipoxen CEO Scott Maguire told ProactiveInvestors.com that the latest project results have confirmed all of the major benefits that were announced in April 2009.

He said that the company will now seek EU grant funding to take their proprietary product into the clinic as soon as possible.

"I believe that these results put Lipoxen firmly on the map as a leading European platform technology company with the potential to offer a full range of delivery solutions for both biologic and vaccine therapies, be this for next generation drugs and vaccines or for patent protected bio-superior products," Maguire told ProactiveInvestors.com.

Lipoxen has three proprietary patented technology platforms, including PolyXen, ImuXen and SiRNAblate.

[the_doctor] 21/10/2010 19:57

'there must still be a line of cheap stock somewhere'

buywell's?

well, his seems to be getting cheaper anyway! ;o)

[rkhl] 21/10/2010 18:48

Can't believe it did not make it to 7p, there must still be a line of cheap stock somewhere.

[rkhl] 21/10/2010 10:08

Seems to be a bit more interest the last two days! with some good volume!

[rkhl] 21/10/2010 09:45

Looks like the mm's are still taking offers under the current price, think this may tick back up soon to 7p. Great news about the flu vaccine as well. Lets hope we get some more good news next week.

[drewz] 19/10/2010 11:13

This will 'take off' one day. I think.

[buywell2] 19/10/2010 09:28

RNS Number : 5049U

Lipoxen PLC

18 October 2010

For Immediate Release 18 October 2010


LIPOXEN

LATEST RESULTS ON PROPRIETARY INFLUENZA VACCINE

-- Project results validate positive Efficacy findings for Proprietary Influenza Vaccine candidate

-- Company advancing plans to take product candidate into Phase 1 clinical trials within 24 months.

-- Initiation of search for commercial collaboration to accelerate product development.

Lipoxen plc (AIM: LPX), ('Lipoxen' or 'the Company') a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces positive efficacy results for its novel influenza vaccine using its liposomal co-delivery technology "ImuXen" and is advancing plans to capitalise on this pre-clinical success in order to accelerate the candidate into the clinic within 24 months.

While Lipoxen has provided interim updates to the market on this Technology Strategy Board part-funded project, the agreed project plan has now been successfully concluded with the positive outcome that the Lipoxen formulation induced protective immunity against challenge with live virulent influenza virus after a single vaccination in a mouse model. Importantly, the formulation did not require the addition of an adjuvant and contained considerably less protein antigen than current flu vaccines. Furthermore, a spray dried version of the vaccine was still efficacious even after storage at 37[deg]C for 6 weeks indicating that there is the potential to create a formulation that can withstand storage outside of the cold chain.

In April 2009 the Company announced positive pre-clinical data in respect of this proprietary influenza vaccine candidate, noting that:

1. The ImuXen technology platform, as applied to an influenza vaccine had shown an increase in the effectiveness of influenza vaccines of approximately 30-fold.

2. The technology has the potential to radically increase output of vaccine doses from manufacturing facilities to confer an advantage of up to 10 times existing vaccine production rates - a major benefit when addressing the challenges to human health in situation of both pandemic and seasonal outbreaks.

3. The technology avoids the need for "cold chain" storage and distribution as in its dried form it is stable for long periods at high temperatures

Lipoxen stated at that time that it was necessary to undertake further studies to specifically validate the significant advantages that a novel influenza vaccine produced using the ImuXen platform technology could deliver. These were focused on three key areas:

(a) Economies of production through the use of less antigen.

(b) The ability to confer single-shot immunity

(c) The ability to deliver a cost effective and storage and handling stable product able to be effectively dosed in tropical and sub-tropical climates.

In short, these latest project results have validated all of the major benefits announced 18 months ago and, based on them, the Company has moved directly to seek EU grant funding to assist in meeting the costs of undertaking a full GMP manufacturing and GLP toxicity, safety and efficacy programme ahead of the Company's planned route to Phase I (safety) studies in Man.

Subject to the availability of capital - whether internally, from EU grant funding or through commercial partnering Lipoxen has targeted submitting its clinical trial application in Q4 2012.

Commenting on the announcement, Scott Maguire, CEO said:

"While the vaccine used in this project was designed to mimic current single-strain pandemic vaccines, the ImuXen platform allows the development of multi-valent vaccines with the potential to address the combined demands of therapeutic efficacy and cost effectiveness, the latter being in the light of the continuing demands of governments and other health care payers to reduce the cost of public healthcare.

These trial results have underpinned our belief in the long term viability of the ImuXen platform for the development and efficient production of a broad spectrum of vaccine therapies, and have wholly vindicated our early optimism for both the ImuXen technology in general and the influenza vaccine candidate in particular. We are now actively taking steps to commercialise this opportunity in parallel with seeking EU grant funding to take this important proprietary product into the clinic as soon as possible.

While a specific influenza product may yet be some years away from any market launch - and by no means taking lightly the challenges of clearing the many clinical hurdles to be overcome along the way - the Company has now put a clear line in the sand over the real commercial potential vested in the ImuXen platform which can now look to sit alongside our PolyXen technology which has already shown such great promise in both clinical trials and with our leading commercial collaborator, Baxter Healthcare.

I believe that these results put Lipoxen firmly on the map as a leading European platform technology company with the potential to offer a full range of delivery solutions for both biologic and vaccine therapies, be this for next generation drugs and vaccines or for patent protected bio-superior products."

- Ends -

For further information, please contact:

Enquiries

Lipoxen plc [phone]
M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser) [phone]
Jeff Keating / Claes Spang

Buchanan Communications [phone]
Lisa Baderoon, Mark Court, Jessica Fontaine




About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms:

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products.

Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the GBP2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a GBP1.2 million placing in April 2010 which was led by the Company's management team.

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.

About the Technology Strategy Board

The Technology Strategy Board is a business-led executive non-departmental public body, established by the government. Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business, in order to increase economic growth and improve the quality of life. It is sponsored by the Department for Business, Innovation and Skills (BIS). For further information please visit www.innovateuk.org

This information is provided by RNS

The company news service from the London Stock Exchange

END

[123asd] 18/10/2010 17:02

Seems to me the stock is being drip-fed - any positive news we get is sold into, with pauses to allow the share price to take a breather before the next onslaught...hope they're gone by November.

[rkhl] 18/10/2010 16:37

Anyone with L2 comment on the line of cheap stock that is left, i.e. how much is left on the offer.

[rkhl] 18/10/2010 16:20

Good news but need to see it partnered up before I get excited.

On a side note it's becoming hard to tell what is a sale and what is buy here.

[drewz] 16/10/2010 10:50

I doubt it too. It's just the usual trickle of small sales in quiet times which drifts the price lower. All to play for.

[rkhl] 15/10/2010 20:25

I think people are being too short sighted, yes there are some problems with LPX in that they are going to require more funding next year but there are revenue streams such as the Baxter deal. Yes they may have to go to the market and issue more shares but I don't think it will be the end of the world if this does happen. At a mcap of £10m there is plenty of scope for a re-rating. Obviously the other issue is that clinical trials are out of their hands and that's why we keep getting the delays but on the other hand this does drastically reduce the amount of money LPX needs to do all these trials. Anyway all of this is irrelevant I suppose, where we go from here depends on the results from the EPO P2 trials and other trials and updates over the next month or two. I know one thing selling at 6.2p is selling at a low, this is the time to buy unless of course someone has market information which we are not privy to but I doubt it.

[123asd] 15/10/2010 16:22

That was me, 35k at 6.35p, there's no justification for this fall away, after them getting $2m in the bank last month.

Edit: After market reported 150k sell at 6.25p from 4.10pm

[rkhl] 15/10/2010 16:17

MM's are giving it away, looks like someone just got in at 6.35, might try and get another 10k before the bell.

[123asd] 15/10/2010 13:26

Not yet, I'm hanging fire...

[rkhl] 15/10/2010 13:06

Even when it went below 6p it was still hard to get in at this price because the spread was so wide. Buying opportunity if you believe in the LPX story IMO.

[rkhl] 15/10/2010 13:04

Tempted to buy some more at this price.

[rkhl] 15/10/2010 13:03

Was that you? I notice someone just bought 25k at 6.4p, unless there's an absolute disaster I don't think you can go wrong at that price, just my personal opinion.

[123asd] 15/10/2010 12:22

250k at least being offered at 6.4p....applying the squeeze? News must be very imminent, I'm tempted...

[rkhl] 15/10/2010 11:45

Being given away at the moment - I just bought 10k at 6.4p.